» Articles » PMID: 28950195

Octa-arginine Modified Lipid Emulsions As a Potential Ocular Delivery System for Disulfiram: A Study of the Corneal Permeation, Transcorneal Mechanism and Anti-cataract Effect

Overview
Publisher Elsevier
Specialty Chemistry
Date 2017 Sep 27
PMID 28950195
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

The purpose of the study was to design a novel octa-arginine (R8) modified lipid emulsion (LE) system for the ocular delivery of the lipophilic drug disulfiram (DSF). The influence of the particle size of the lipid emulsions and the presence of R8 on corneal permeation was studied. DSF-loaded lipid emulsions with different particle sizes (DSF-LE1, DSF-LE2, DSF-LE3) and DSF-loaded lipid emulsions modified with R8 (DSF-LE1-R8 and DSF-LE2-R8) were prepared. The Zeta potential of the lipid emulsions was changed from negative to a positive value after modification of R8. The mucoadhesion of different preparations was investigated, and DSF-LE1-R8 was found to produce the strongest mucoadhesion. The in vitro corneal penetration study and in vivo ocular distribution study showed that the R8 modified lipid emulsion (DSF-LE1-R8) with a nano particle size, exhibited the highest permeability and the largest amount of DDC distributed in ocular issues. Coumarin-6 labelled LE1-R8 displayed more homogeneous fluorescence with the deeper penetration into the cornea compared with other preparations at various times. Confocal laser scanning microscopy showed that, in addition to paracellular routes, LE-R8 could also transport across the corneal epithelium by transcellular routes as a result of increased uptake due to the R8 modification. Furthermore, the anti-cataract effect was evaluated and it was found that DSF-LE1-R8 exhibited a marked anti-cataract effect. Therefore, the lipid emulsions with nano-sized particles and modification of R8 were proposed as a potential ocular delivery system to improve the corneal penetration and ocular delivery of DSF.

Citing Articles

Breaking Barriers: Nanomedicine-Based Drug Delivery for Cataract Treatment.

Chen Y, Ye Z, Chen H, Li Z Int J Nanomedicine. 2024; 19:4021-4040.

PMID: 38736657 PMC: 11086653. DOI: 10.2147/IJN.S463679.


Polymer Nanoparticles with 2-HP-β-Cyclodextrin for Enhanced Retention of Uptake into HCE-T Cells.

Qin Z, Li B, Deng Q, Wen Y, Feng S, Duan C Molecules. 2024; 29(3).

PMID: 38338402 PMC: 10856407. DOI: 10.3390/molecules29030658.


Recent Advances of Ocular Drug Delivery Systems: Prominence of Ocular Implants for Chronic Eye Diseases.

Mostafa M, Al Fatease A, Alany R, Abdelkader H Pharmaceutics. 2023; 15(6).

PMID: 37376194 PMC: 10302848. DOI: 10.3390/pharmaceutics15061746.


Construction and Evaluation of Hyaluronic Acid-Coated Flurbiprofen-Layered Double Hydroxide Ocular Drug Delivery System.

Gu D, Pan H, Xu S, Chen W, Zhu R, Jiang W AAPS PharmSciTech. 2022; 23(8):287.

PMID: 36266593 DOI: 10.1208/s12249-022-02418-2.


Fluorescent Nanosystems for Drug Tracking and Theranostics: Recent Applications in the Ocular Field.

Zingale E, Romeo A, Rizzo S, Cimino C, Bonaccorso A, Carbone C Pharmaceutics. 2022; 14(5).

PMID: 35631540 PMC: 9147643. DOI: 10.3390/pharmaceutics14050955.